Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.33 |
| ▸ | CASP1 | P29466 | 3/20 | 0.33 |
| ▸ | CASP7 | P55210 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30366404 | 0.89 | — | — | |
| SCHEMBL21820230 | 0.89 | — | — | |
| SCHEMBL21883631 | 0.88 | CYP1A2 (0.33) | CYP1A2ALDH1A1HSD17B10CYP2C19CASP1 | |
| SCHEMBL25015259 | 0.79 | CYP1A2 (0.39) | CYP1A2ALDH1A1HSD17B10CYP2C19CASP1 | |
| SCHEMBL23084964 | 0.78 | CTSL (0.35) | CYP1A2ALDH1A1HSD17B10CYP2C19CASP1 | |
| SCHEMBL3095607 | 0.78 | TRPA1 (0.31) | — | |
| SCHEMBL21820317 | 0.77 | NCOA1 (0.33) | MEN1KMT2A | |
| SCHEMBL30236867 | 0.77 | NCOA1 (0.33) | MEN1KMT2A | |
| SCHEMBL21883271 | 0.77 | ALDH1A1 (0.37) | CYP1A2ALDH1A1HSD17B10CYP2C19CASP1 | |
| SCHEMBL3102060 | 0.77 | BRPF1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111527093-B | Antibacterial heterocyclic compounds and synthesis thereof | 巴格沃克斯研究有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3717490-B1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | BUGWORKS RES INC (US) | 2023-05-24 | — | — | EP | disclosed |
| CN-110382505-B | Heterocyclic compounds useful as antibacterial agents and process for producing the same | 巴格沃克斯研究有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11401277-B2 | Anti-bacterial heterocyclic compounds and their synthesis | Bugworks Research, Inc. (US) | 2022-08-02 | — | — | US | disclosed |
| US-20210070772-A1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | Bugworks Research, Inc. | 2021-03-11 | — | — | US | disclosed |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | Bugworks Research, Inc. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | Bugworks Research, Inc. (US) | 2021-02-09 | — | — | US | disclosed |
| CN-111527093-A | Antibacterial heterocyclic compounds and synthesis thereof | 巴格沃克斯研究有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | Bugworks Research, Inc. | 2020-03-19 | — | — | US | disclosed |
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | Bugworks Research, Inc. | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | UROD, ALPI, HLA-A | CYP1A2 753/4885ALDH1A1 1655/4885HSD17B10 1170/4885 |
| US-20210070772-A1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | HLA-B, BAX, REN | CYP1A2 525/4885ALDH1A1 2677/4885HSD17B10 1276/4885 |
| US-11401277-B2 | Anti-bacterial heterocyclic compounds and their synthesis | HLA-B, BAX, REN | CYP1A2 525/4885ALDH1A1 2677/4885HSD17B10 1276/4885 |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | UROD, ALPI, HLA-A | CYP1A2 753/4885ALDH1A1 1655/4885HSD17B10 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.